Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor.
BACKGROUND
The androgen receptor (AR) plays important roles in the development of male phenotype and in different human diseases including prostate cancers. The AR can act either as a promoter or a tumor suppressor depending on cell types. The AR proliferative response program has been well studied, but its prohibitive response program has not yet been thoroughly studied.


RESULTS
Previous studies found that PC3 cells expressing the wild-type AR inhibit growth and suppress invasion. We applied expression profiling to identify the response program of PC3 cells expressing the AR (PC3-AR) under different growth conditions (i.e. with or without androgens and at different concentration of androgens) and then applied the newly developed ChIP-seq technology to identify the AR binding regions in the PC3 cancer genome. A surprising finding was that the comparison of MOCK-transfected PC3 cells with AR-transfected cells identified 3,452 differentially expressed genes (two fold cutoff) even without the addition of androgens (i.e. in ethanol control), suggesting that a ligand independent activation or extremely low-level androgen activation of the AR. ChIP-Seq analysis revealed 6,629 AR binding regions in the cancer genome of PC3 cells with an FDR (false discovery rate) cut off of 0.05. About 22.4% (638 of 2,849) can be mapped to within 2 kb of the transcription start site (TSS). Three novel AR binding motifs were identified in the AR binding regions of PC3-AR cells, and two of them share a core consensus sequence CGAGCTCTTC, which together mapped to 27.3% of AR binding regions (1,808/6,629). In contrast, only about 2.9% (190/6,629) of AR binding sites contains the canonical AR matrix M00481, M00447 and M00962 (from the Transfac database), which is derived mostly from AR proliferative responsive genes in androgen dependent cells. In addition, we identified four top ranking co-occupancy transcription factors in the AR binding regions, which include TEF1 (Transcriptional enhancer factor), GATA (GATA transcription factors), OCT (octamer transcription factors) and PU1 (PU.1 transcription factor).


CONCLUSIONS
Our data provide a valuable data set in understanding the molecular basis for growth inhibition response program of the AR in prostate cancer cells, which can be exploited for developing novel prostate cancer therapeutic strategies.
Lin
Biaoyang
B
Department of Urology, University of Washington, Seattle, WA, USA. biaoylin@gmail.com
Wang
Jun
J
Hong
Xu
X
Yan
Xiaowei
X
Hwang
Daehee
D
Cho
Ji-Hoon
JH
Yi
Danielle
D
Utleg
Angelita G
AG
Fang
Xuefeng
X
Schones
Dustin E
DE
Zhao
Keji
K
Omenn
Gilbert S
GS
Hood
Leroy
L
D045744:Cell Line, Tumor; D047369:Chromatin Immunoprecipitation; D002892:Chromosomes, Human, Pair 22; D015536:Down-Regulation; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D011485:Protein Binding; D011944:Receptors, Androgen / Q000378:metabolism / Q000502:physiology*
D011944:Receptors, Androgen